Massimo Gadina

List of Publications by Year
in descending order

106 papers	18,520 citations	30070 54 h-index	25787 108 g-index
115 all docs	115 docs citations	115 times ranked	21270 citing authors

#	Article	IF	Citations
1	Affecting the effectors: JAK inhibitors modulation of immune cell numbers and functions in patients with rheumatoid arthritis. Expert Review of Clinical Immunology, 2022, 18, 309-319.	3.0	12
2	Jakinibs of All Trades: Inhibiting Cytokine Signaling in Immune-Mediated Pathologies. Pharmaceuticals, 2022, 15, 48.	3.8	16
3	Janus kinase (JAK) inhibition with baricitinib in refractory juvenile dermatomyositis. Annals of the Rheumatic Diseases, 2021, 80, 406-408.	0.9	53
4	Pleiotropic consequences of metabolic stress for the major histocompatibility complex class II molecule antigen processing and presentation machinery. Immunity, 2021, 54, 721-736.e10.	14.3	30
5	Homozygous variant p. Arg90His in NCF1 is associated with early-onset Interferonopathy: a case report. Pediatric Rheumatology, 2021, 19, 54.	2.1	4
6	JAK inhibitors: Ten years after. European Journal of Immunology, 2021, 51, 1615-1627.	2.9	49
7	JAK1: Number one in the family; number one in inflammation?. Rheumatology, 2021, 60, ii3-ii10.	1.9	28
8	Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nature Communications, 2021, 12, 3391.	12.8	93
9	A Decade of JAK Inhibitors: What Have We Learned and What May Be the Future?. Arthritis and Rheumatology, 2021, 73, 2166-2178.	5.6	43
10	3-hydroxy-L-kynurenamine is an immunomodulatory biogenic amine. Nature Communications, 2021, 12, 4447.	12.8	30
11	Granzyme A and CD160 expression delineates ILC1 with graded functions in the mouse liver. European Journal of Immunology, 2021, 51, 2568-2575.	2.9	28
12	Somatic Mutations in <i>UBA1</i> Define a Distinct Subset of Relapsing Polychondritis Patients With VEXAS. Arthritis and Rheumatology, 2021, 73, 1886-1895.	5.6	125
13	EAACI Biologicals Guidelinesâ€"dupilumab for children and adults with moderateâ€toâ€severe atopic dermatitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 988-1009.	5.7	24
14	JAK-STAT signaling in human disease: From genetic syndromes to clinical inhibition. Journal of Allergy and Clinical Immunology, 2021, 148, 911-925.	2.9	57
15	High throughput pSTAT signaling profiling by fluorescent cell barcoding and computational analysis. Journal of Immunological Methods, 2020, 477, 112667.	1.4	8
16	Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease. Nature, 2020, 577, 103-108.	27.8	198
17	Somatic Mutations in <i>UBA1</i> and Severe Adult-Onset Autoinflammatory Disease. New England Journal of Medicine, 2020, 383, 2628-2638.	27.0	580
18	HiJAKing SARS-CoV-2? The potential role of JAK inhibitors in the management of COVID-19. Science Immunology, 2020, 5, .	11.9	94

#	Article	IF	Citations
19	SnapShot: Jak-STAT Signaling II. Cell, 2020, 181, 1696-1696.e1.	28.9	53
20	Type 2 immunity in the skin and lungs. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 1582-1605.	5.7	304
21	Expression of interferon-regulated genes in juvenile dermatomyositis versus Mendelian autoinflammatory interferonopathies. Arthritis Research and Therapy, 2020, 22, 69.	3.5	39
22	Translating JAKs to Jakinibs. Journal of Immunology, 2020, 204, 2011-2020.	0.8	46
23	Tofacitinib inhibits the development of experimental autoimmune uveitis and reduces the proportions of Th1 but not of Th17 cells. Molecular Vision, 2020, 26, 641-651.	1.1	10
24	Cytokines and Cytokine Receptors. , 2019, , 127-155.e1.		44
25	Protein Kinase Antagonists in Therapy of Immunological and Inflammatory Diseases. , 2019, , 1185-1196.e1.		2
26	Transcriptional, Epigenetic and Pharmacological Control of JAK/STAT Pathway in NK Cells. Frontiers in Immunology, 2019, 10, 2456.	4.8	8
27	Janus kinases to jakinibs: from basic insights to clinical practice. Rheumatology, 2019, 58, i4-i16.	1.9	111
28	Second Case of HOIP Deficiency Expands Clinical Features and Defines Inflammatory Transcriptome Regulated by LUBAC. Frontiers in Immunology, 2019, 10, 479.	4.8	54
29	183â€…A phase 1B/2A trial of tofacitinib, an oral janus kinase inhibitor, in systemic lupus erythematosus. , 2019, , .		8
30	JAK Inhibition Differentially Affects NK Cell and ILC1 Homeostasis. Frontiers in Immunology, 2019, 10, 2972.	4.8	6
31	Selective Janus kinase inhibitors come of age. Nature Reviews Rheumatology, 2019, 15, 74-75.	8.0	64
32	Tofacitinib enhances delivery of antibody-based therapeutics to tumor cells through modulation of inflammatory cells. JCI Insight, 2019, 4, .	5.0	17
33	Development of a Validated Interferon Score Using NanoString Technology. Journal of Interferon and Cytokine Research, 2018, 38, 171-185.	1.2	120
34	Germline gain-of-function myeloid differentiation primary response geneâ€“88 (MYD88) mutation in a child with severe arthritis. Journal of Allergy and Clinical Immunology, 2018, 141, 1943-1947.e9.	2.9	14
35	Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors. Annals of the Rheumatic Diseases, 2018, 77, 612-619.	0.9	49
36	Pharmacokinetics, Pharmacodynamics, and Proposed Dosing of the Oral JAK1 and JAK2 Inhibitor Baricitinib in Pediatric and Young Adult CANDLE and SAVI Patients. Clinical Pharmacology and Therapeutics, 2018, 104, 364-373.	4.7	93

#	Article	IF	Citations
37	JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies. Journal of Clinical Investigation, 2018, 128, 3041-3052.	8.2	387
38	<scp>JAK</scp>/<scp>STAT</scp> signaling in regulation of innate lymphoid cells: The gods before the guardians. Immunological Reviews, 2018, 286, 148-159.	6.0	51
39	Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs. Journal of Leukocyte Biology, 2018, 104, 499-514.	3.3	122
40	Cerebrospinal Fluid Cytokines Correlate With Aseptic Meningitis and Bloodâ€"Brain Barrier Function in Neonatalâ€Onset Multisystem Inflammatory Disease: Central Nervous System Biomarkers in Neonatalâ€Onset Multisystem Inflammatory Disease Correlate With Central Nervous System Inflammation. Arthritis and Rheumatology, 2017, 69, 1325-1336.	5.6	50
41	JAKâ€"STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects. Drugs, 2017, 77, 521-546.	10.9	711
42	Dense genotyping of immune-related loci implicates host responses to microbial exposure in BehÃ§et's disease susceptibility. Nature Genetics, 2017, 49, 438-443.	21.4	129
43	Brief Report: Deficiency of Complement 1r Subcomponent in Earlyâ€Onset Systemic Lupus Erythematosus: The Role of Diseaseâ€Modifying Alleles in a Monogenic Disease. Arthritis and Rheumatology, 2017, 69, 1832-1839.	5.6	38
44	JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nature Reviews Drug Discovery, 2017, 16, 843-862.	46.4	759
45	Small molecules to the rescue: Inhibition of cytokine signaling in immune-mediated diseases. Journal of Autoimmunity, 2017, 85, 20-31.	6.5	67
46	Generation and differentiation of induced pluripotent stem cells reveal ankylosing spondylitis risk gene expression in bone progenitors. Clinical Rheumatology, 2017, 36, 143-154.	2.2	17
47	Tofacitinib Ameliorates Murine Lupus and Its Associated Vascular Dysfunction. Arthritis and Rheumatology, 2017, 69, 148-160.	5.6	183
48	HiJAKing Innate Lymphoid Cells?. Frontiers in Immunology, 2017, 8, 438.	4.8	14
49	Abstract 3023: The antitumor activity of immunotoxins is enhanced by tofacitinib. Cancer Research, 2017, 77, 3023-3023.	0.9	1
50	Biallelic hypomorphic mutations in a linear deubiquitinase define otulipenia, an early-onset autoinflammatory disease. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 10127-10132.	7.1	206
51	Targeting cytokine signaling in autoimmunity: back to the future and beyond. Current Opinion in Immunology, 2016, 43, 89-97.	5.5	47
52	Whole Chromosome Instability induces senescence and promotes SASP. Scientific Reports, 2016, 6, 35218.	3.3	117
53	Type I/II cytokines, JAKs, and new strategies for treating autoimmune diseases. Nature Reviews Rheumatology, 2016, 12, 25-36.	8.0	468
54	Loss-of-function mutations in TNFAIP3 leading to A20 haploinsufficiency cause an early-onset autoinflammatory disease. Nature Genetics, 2016, 48, 67-73.	21.4	513

#	Article	IF	Citations
55	Editorial: Decernotinib: A Nextâ€Generation Jakinib. Arthritis and Rheumatology, 2016, 68, 31-34.	5.6	38
56	Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature, 2015, 520, 558-562.	27.8	323
57	The JAK-STAT Pathway: Impact on Human Disease and Therapeutic Intervention. Annual Review of Medicine, 2015, 66, 311-328.	12.2	1,074
58	Additive loss-of-function proteasome subunit mutations in CANDLE/PRAAS patients promote type I IFN production. Journal of Clinical Investigation, 2015, 125, 4196-4211.	8.2	258
59	Reversal of CD8 T-Cellâ€"Mediated Mucocutaneous Graft-Versus-Host-Like Disease by the JAK Inhibitor Tofacitinib. Journal of Investigative Dermatology, 2014, 134, 992-1000.	0.7	61
60	Jakpot! New small molecules in autoimmune and inflammatory diseases. Experimental Dermatology, 2014, 23, 7-11.	2.9	105
61	Activated STING in a Vascular and Pulmonary Syndrome. New England Journal of Medicine, 2014, 371, 507-518.	27.0	1,074
62	Early-Onset Stroke and Vasculopathy Associated with Mutations in ADA2. New England Journal of Medicine, 2014, 370, 911-920.	27.0	687
63	A173: Cerebrospinal Fluid Cytokines Correlate With Innate Immune Cells in Neonatal Onset Multisystem Inflammatory Disease (NOMID) Patients in Clinical Remission Treated With Anakinra. Arthritis and Rheumatology, 2014, 66, S226-S226.	5.6	4
64	Advances in kinase inhibition. Current Opinion in Rheumatology, 2014, 26, 237-243.	4.3	15
65	Janus Kinases: An Ideal Target for the Treatment of Autoimmune Diseases. Journal of Investigative Dermatology Symposium Proceedings, 2013, 16, S70-S72.	0.8	29
66	The Arrival of JAK Inhibitors: Advancing the Treatment of Immune and Hematologic Disorders. BioDrugs, 2013, 27, 431-438.	4.6	84
67	Cytokines and cytokine receptors. , 2013, , 108-135.		8
68	Kinase inhibitors in the treatment of immune-mediated disease. F1000 Medicine Reports, 2012, 4, 5.	2.9	53
69	Modulation of Innate and Adaptive Immune Responses by Tofacitinib (CP-690,550). Journal of Immunology, 2011, 186, 4234-4243.	0.8	569
70	Cytokine Signaling: Birth of a Pathway. Journal of Immunology, 2011, 187, 5475-5478.	0.8	44
71	Accurate and Simple Measurement of the Pro-inflammatory Cytokine IL-1β using a Whole Blood Stimulation Assay. Journal of Visualized Experiments, 2011, , .	0.3	6
72	A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: Description of two unrelated cases from Brazil. Arthritis and Rheumatism, 2011, 63, 4007-4017.	6.7	96

#	Article	IF	Citations
73	Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with BehÃ§et's disease. Nature Genetics, 2010, 42, 698-702.	21.4	595
74	USP17 Regulates Ras Activation and Cell Proliferation by Blocking RCE1 Activity. Journal of Biological Chemistry, 2009, 284, 9587-9595.	3.4	72
75	Immune modulation: Turncoat regulatory T cells. Nature Medicine, 2009, 15, 1365-1365.	30.7	4
76	An Autoinflammatory Disease with Deficiency of the Interleukin-1â€"Receptor Antagonist. New England Journal of Medicine, 2009, 360, 2426-2437.	27.0	892
77	Respiratory Syncytial Virus NS1 Protein Degrades STAT2 by Using the Elongin-Cullin E3 Ligase. Journal of Virology, 2007, 81, 3428-3436.	3.4	153
78	Cytohesin Binder and Regulator Augments T Cell Receptor-induced Nuclear Factor of Activated T CellsÂ·AP-1 Activation through Regulation of the JNK Pathway. Journal of Biological Chemistry, 2006, 281, 19985-19994.	3.4	13
79	Cytohesin Binder and Regulator (Cybr) Is Not Essential for T- and Dendritic-Cell Activation and Differentiation. Molecular and Cellular Biology, 2006, 26, 6623-6632.	2.3	18
80	Immunodeficiency Is A Tough Nut to CRAC: The Importance of Calcium Flux in T Cell Activation. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2006, 6, 253-256.	3.4	8
81	CXCL12 Signaling Is Independent of Jak2 and Jak3. Journal of Biological Chemistry, 2005, 280, 17408-17414.	3.4	40
82	Gi-Protein-Dependent Inhibition of IL-12 Production Is Mediated by Activation of the Phosphatidylinositol 3-Kinase-Protein 3 Kinase B/Akt Pathway and JNK. Journal of Immunology, 2005, 175, 2994-2999.	0.8	89
83	Viral FLIP Impairs Survival of Activated T Cells and Generation of CD8+ T Cell Memory. Journal of Immunology, 2004, 172, 6313-6323.	0.8	45
84	Ubiquitination for activation: new directions in the NF-kappaB roadmap. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2004, 4, 144-6.	3.4	9
85	Cytokines and transcription factors that regulate T helper cell differentiation: new players and new insights. Journal of Clinical Immunology, 2003, 23, 147-161.	3.8	324
86	New interleukins: are there any more?. Current Opinion in Infectious Diseases, 2003, 16, 211-217.	3.1	13
87	Cybr, a cytokine-inducible protein that binds cytohesin-1 and regulates its activity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 2625-2629.	7.1	39
88	STAT4 serine phosphorylation is critical for IL-12-induced IFN-Â production but not for cell proliferation. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 12281-12286.	7.1	192
89	Cytokines and their role in lymphoid development, differentiation and homeostasis. Current Opinion in Allergy and Clinical Immunology, 2002, 2, 495-506.	2.3	81
90	Critical Role for STAT4 Activation by Type 1 Interferons in the Interferon-Î³ Response to Viral Infection. Science, 2002, 297, 2063-2066.	12.6	443

#	Article	IF	Citations
91	Cytokine Signaling in 2002. Cell, 2002, 109, S121-S131.	28.9	978
92	Mammary tumors in mice conditionally mutant for Brca1 exhibit gross genomic instability and centrosome amplification yet display a recurring distribution of genomic imbalances that is similar to human breast cancer. Oncogene, 2002, 21, 5097-5107.	5.9	140
93	Fyn kinase initiates complementary signals required for IgE-dependent mast cell degranulation. Nature Immunology, 2002, 3, 741-748.	14.5	422
94	ROLE OF CYTOKINES IN CANCER CACHEXIA IN A MURINE MODEL OF INTRACEREBRAL INJECTION OF HUMAN TUMOURS. Cytokine, 2001, 15, 27-38.	3.2	32
95	Unexpected Effects of FERM Domain Mutations on Catalytic Activity of Jak3. Molecular Cell, 2001, 8, 959-969.	9.7	127
96	Signaling by Type I and II cytokine receptors: ten years after. Current Opinion in Immunology, 2001, 13, 363-373.	5.5	192
97	Inducible Expression of Stat4 in Dendritic Cells and Macrophages and Its Critical Role in Innate and Adaptive Immune Responses. Journal of Immunology, 2001, 166, 4446-4455.	0.8	172
98	Cytokine regulation of IL-12 receptor Î²2 expression: differential effects on human T and NK cells. European Journal of Immunology, 2000, 30, 1364-1374.	2.9	63
99	Inhibition of Th1 Immune Response by Glucocorticoids: Dexamethasone Selectively Inhibits IL-12-Induced Stat4 Phosphorylation in T Lymphocytes. Journal of Immunology, 2000, 164, 1768-1774.	0.8	228
100	Hierarchy of Protein Tyrosine Kinases in Interleukin-2 (IL-2) Signaling: Activation of Syk Depends on Jak3; However, Neither Syk nor Lck Is Required for IL-2-Mediated STAT Activation. Molecular and Cellular Biology, 2000, 20, 4371-4380.	2.3	35
101	IL-12 Receptor Î²2 (IL-12RÎ²2)-Deficient Mice Are Defective in IL-12-Mediated Signaling Despite the Presence of High Affinity IL-12 Binding Sites. Journal of Immunology, 2000, 165, 6221-6228.	0.8	147
102	The Docking Molecule Gab2 Is Induced by Lymphocyte Activation and Is Involved in Signaling by Interleukin-2 and Interleukin-15 but Not Other Common Î³ Chain-using Cytokines. Journal of Biological Chemistry, 2000, 275, 26959-26966.	3.4	75
103	Germline Mutations in the Extracellular Domains of the 55 kDa TNF Receptor, TNFR1, Define a Family of Dominantly Inherited Autoinflammatory Syndromes. Cell, 1999, 97, 133-144.	28.9	1,271
104	Preclinical evaluation of the ribosome-inactivating proteins PAP-1, PAP-S and RTA in mice. International Journal of Immunopharmacology, 1995, 17, 829-839.	1.1	15
105	A Study of the Intracellular Routing of Cytotoxic Ribonucleases. Journal of Biological Chemistry, 1995, 270, 17476-17481.	3.4	86
106	Diffferential sensitivity of in vivo TNF and IL-6 production to modulation by anti-inflammatory drugs in mice. International Journal of Immunopharmacology, 1992, 14, 1045-1050.	1.1	51